Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C

Ogawa, Eiichi; Nomura, Hideyuki; Nakamuta, Makoto; Furusyo, Norihiro; Kajiwara, Eiji; Dohmen, Kazufumi; Kawano, Akira; Ooho, Aritsune; Azuma, Koichi; Takahashi, Kazuhiro; Satoh, Takeaki; Koyanagi, Toshimasa; Ichiki, Yasunori; Kuniyoshi, Masami; Yanagita, Kimihiko; Amagase, Hiromasa; Morita, Chie; Sugimoto, Rie; Kato, Masaki; Shimoda, Shinji; Hayashi, Jun

doi:10.3390/cancers12092602

Cited by 11 publications

(15 citation statements)

References 35 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, we found that AFP had the best diagnostic accuracy for prediction of HCC following DAAs (75.5%) in comparison to APRI (68.7%) and FIB-4 (60.1%). In consistent with the current study, Ogawa et al (9) showed that age > 70 (odds ratio= 2.39), male sex (odds ratio= 2.07), cirrhosis (odds ratio= 2.97), serum albumin < 3.5 g/dL (odds ratio= 2.72), and AFP > 7 ng/ml (odds ratio= 4.92) are considered risk factors for the development of HCC in patients received DAAs. In contrast to the current study, Conti et al (10) stated that baseline AFP level wasn't a risk HCC following DAAs.…”

Section: Discussionsupporting

confidence: 90%

Incidence of Hepatocellular Carcinoma in Patient with Elevated Alpha Fetoprotein before DAAS

Shafi¹,

Ali²,

Morsey³

2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Management of chronic infection with hepatitis C virus (HCV) with direct acting antivirals (DAAs) agents achieves high virological response. Recently, there is a matter of controversy about occurrence of hepatocellular carcinoma (HCC) following those agents. Objective: This study aimed to evaluate the efficacy of alpha fetoprotein (AFP) in development of HCC following DAAs therapy. Patients and methods: two hundred patients with chronic HCV infection who were eligible for DAAs therapy were recruited. Those patients were followed up for one year following therapy to detect development of HCC. Patients were grouped into either with normal AFP (100 patients) or high AFP (100 patients). Results: Majority (84%) of patients were males with overall mean age of 43.87±12.76 years. There were no significant differences between both groups of patients as regard baseline data. With exception of 4% of patients, all of them reached the sustained virological response (SVR). Frequency of HCC detection was higher among those patients with high AFP (9 (9%) vs 1 (1%); P< 0.001). We found that liver cirrhosis; FIB-4, APRI and AFP were predictors for HCC. AFP had the best diagnostic accuracy for prediction of HCC following DAAs Conclusion: Patients who received DAAs for HCV infection should be regularly screened for development of HCC.

show abstract

Section: Discussionsupporting

confidence: 90%

Incidence of Hepatocellular Carcinoma in Patient with Elevated Alpha Fetoprotein before DAAS

Shafi¹,

Ali²,

Morsey³

2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, the debate continues about DAAs treatment and development of HCC. Some studies have shown that DAAs treatment was not associated with an increase in the development of HCC [58,59]. Other studies have shown conflicting results, indicating that DAAs therapy is associated with an increase in the recurrence of HCC in patients previously cured by liver transplantation [60].…”

Section: Impact Of Current Antiviral Therapies In the Clinical Outcommentioning

confidence: 99%

Host-Targeting Antivirals for Treatment of Hepatitis C

Kitab¹,

Kohara²,

Tsukiyama-Kohara³

2021

Advances in Hepatology

View full text Add to dashboard Cite

Treatment of chronic hepatitis C virus (HCV) infection has been revolutionized during last years with the development of highly potent direct-acting antivirals (DAAs) specifically targeting HCV proteins. DAAs are the current standard of care for patients with chronic hepatitis C, leading to high cure rates. However, some hurdles exist including the high cost of these therapies restricting access to patients, their inability to protect against the risk of developing hepatocellular carcinoma in patients with advanced fibrosis, and emergence of resistant variants resulting in treatment failure. New therapeutic options should be essential to overcome DAAs limitations and improve survival. By targeting host-cell factors involved in HCV life cycle, host-targeting antivirals (HTAs) offer opportunity for promising anti-HCV therapy with low mutational rate and may act in a synergistic manner with DAAs to prevent viral resistance and reduce viral replication. Moreover, HTAs could be effective in difficult-to-cure patients by acting through complementary mechanisms. In this chapter, we will focus on the latest and most relevant studies regarding the host-cell factors required in HCV infection and explored as targets of antiviral therapy, we will also discuss the HTAs evaluated in preclinical and clinical development and their potential role as alternative or complementary therapeutic strategies.

show abstract

“…It is ranked as the fifth and ninth most common malignant tumor in men and women, respectively [ 1 , 2 ]. Hepatitis C virus (HCV) was historically one of the leading causes of hepatocellular carcinoma (HCC) and liver-related mortality [ 3 ]. It is among the most feared long-term complications for HCC patients [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients

Khan

Ahmad

Hashem

et al. 2022

JCM

View full text Add to dashboard Cite

The Fibroblast Growth Factor Receptors (FGFRs) are known to regulate cancer metabolism in different tumor types, including hepatocellular carcinoma (HCC). Several risk factors are associated with HCC, of which viral infections (Hepatitis B and C) and cirrhosis are prominent. In Pakistan as well as in highly developed countries like the United States, hepatitis C virus HCV infections are most commonly reported in HCC. Here, we aimed to investigate the clinical relevance of FGFR receptors in HCC and their role in HCV-positive HCC cases. 264 HCC samples along with their clinical information and 96 normal liver samples were collected. qPCR was done to estimate the expression of FGFR1, FGFR2, FGFR3 and FGFR4. Three independent HCV-induced HCC cohorts (containing 293 HCC samples) were used for validation. According to in vitro results, FGFR1 was upregulated in HCV+ HCC patients. However, in all three independent cohorts of HCC, significant a down-regulation of FGFR1 was observed. FGFR2 overexpression was observed in the in vitro cohort as well as in three independent HCC cohorts. Interestingly, a strong correlation of FGFR2 expression was observed between cirrhosis and HCV in all four HCC cohorts. Our study suggested that FGFR2 expression can be used to classify HCC patients based on HCV infection. This FGFR2-based classification may lead to new therapeutic strategies against HCV-positive HCC subtypes.

show abstract

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C

Cited by 11 publications

References 35 publications

Incidence of Hepatocellular Carcinoma in Patient with Elevated Alpha Fetoprotein before DAAS

Incidence of Hepatocellular Carcinoma in Patient with Elevated Alpha Fetoprotein before DAAS

Host-Targeting Antivirals for Treatment of Hepatitis C

Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients

Contact Info

Product

Resources

About